AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Phibro Animal Health Corporation
Video analysis: PAHC
All videosNo video analysis for this stock yet. Request one from our team.
News: PAHC
Why Phibro Animal Health (PAHC) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Phibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. President & Chief Executive Officer, Daniel Bendheim; Chief Operating Officer, Larry Miller; and Chief Financial Officer, Glenn David will address financial analysts and investors on Tuesday, September 15, 2026, at 1:05 PM ET at New York Marriott Marquis in New York. The live audio presentation will be available on the.
PAHC or LMAT: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks is more attractive to value investors?
Phibro Animal Health: Zoetis Integrated And Better Cash Flow Ahead
Phibro Animal Health's Zoetis MFA acquisition has created a larger animal health platform with stronger earnings and broader manufacturing reach. Vaccines, nutritional specialties, and companion-animal expansion give PAHC newer growth verticals beyond the legacy MFA franchise. Management's optimization program and Chicago Heights consolidation could improve efficiency as the acquired portfolio moves beyond integration.
Phibro Animal Health Q4 Earnings Call Highlights
Phibro Animal Health (NASDAQ: PAHC) reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phibro Forward program. For the fiscal year ended June 30, 2026, Phibro posted
Phibro Animal Health Corporation (PAHC) Q4 2026 Earnings Call Transcript
Phibro Animal Health Corporation (PAHC) Q4 2026 Earnings Call Transcript
Phibro Animal Health Q4 Earnings Call Highlights
Phibro Animal Health NASDAQ: PAHC reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phibro Forward program.
Phibro (PAHC) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
